FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052612797> ?p ?o ?g. }

• W2052612797 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CABackground: Total and CD4 lymphopenia is observed in 25% of advanced cancers patients and is a predictive factor of chemotherapy (CT)-induced death, febrile neutropenia, thrombocytopenia, anemia, as well as an independent prognostic factor for survival and tumor progression. CYT107 is a glycosylated recombinant human IL-7 (CYTHERIS, France) emerging as a promising immuno-restorative agent well tolerated in Phase 1 trials. To date, it is unknown whether IL-7 can correct lymphopenia during CT and whether this could translate into clinical benefit in advanced cancer patients.Methods: A placebo-controlled, monocentric, Phase 2a ([NCT01368107][1]) was conducted in lymphopenic metastatic breast cancer (MBC) patients to be treated by capecitabine (2500mg/m2/d, pers os, 21-day cycle from D21 after randomization). Using a 2x2 factorial design, patients were randomly allocated to 4 arms to receive 1) before the 1st cycle of CT : r-hIL-7 (CYT107:10µg/kg, subcutaneously, weekly at D0, D7, D14, groups 2 & 4) or placebo (groups 1 & 3), then 2) during the 3rd cycle of CT: r-hIL-7 (weekly at D57, D64, D71, groups 3 & 4) or placebo (groups 1 & 2). The primary endpoint, CD4 count evolution, was evaluated before (D0 to D21) and during CT (D57 to D78). Secondary endpoints include risks of severe hematological AE, safety and progression free survival (PFS). An ancillary study has evaluated the quantitative and functional changes in circulating immune cells (see abstract Menetrier-Caux).Results: From Nov. 2011 to Jun. 2013, 20 patients (median age [range]: 60 [39-76 y.]; median CD4 count on D0: 242 [22-522 cells/µL]) with MBC (mainly with bone and liver metastasis) were enrolled. Before CT (n=20), r-hIL-7 treatment induced a significant increase of CD4 count (median relative evolution: +148.1% [41.8-763.9 cells/µL] in r-hIL-7 groups vs +9.9% [-50.3-102.2 cells/µL] in placebo [Wilcoxon, p=0.002]). During CT (n=11), r-hIL-7 treatment also increased CD4 count (+58.6%[-15.2-281.5 cells/µL] in r-hIL-7 groups vs -2.4% [-27.6-112.5 cells/µL] in placebo [p=0.121]). Overall, r-hIL-7 was well tolerated with reactions related to injection as the main specific AE, no binding or neutralizing antibodies, and no r-hIL-7-related ≥ Grade 3 AE except 1 fatal SAE for which one a relationship to r-hIL-7 cannot be ruled out. Interestingly, r-hIL-7 treatment during CT reduced the incidence of Grade 3 hematological AE compared to placebo (0 vs 5 events, respectively). PFS data will be available by Feb. 2014.Conclusion: In this exploratory trial, r-hIL-7 treatment was safe at biologically active dose, able to correct CD4 lymphopenia and associated with lower incidence of severe hematological toxicity during CT. These early results are encouraging and warrant further investigations of IL-7 clinical applications in the oncology field.Citation Format: Ray-Coquard Isabelle, Olivier Tredan, Gwenaele Garin, Christine Menetrier-Caux, Sylvie Chabaud, Thomas Bachelot, Claire Cropet, Pierre-Etienne Heudel, Paul Rebattu, Patricia Dupont, Estelle Verronese, Anne-claire Cadore, Valerie Fouillat, Olfa Derbel, Nathalie Bonnin, Therese Croughs, Michel Morre, Nicolas Pasqual, Manuari Manuel, Gilles Clapisson, Christophe Caux, David Perol, Jean-Yves Blay. Elypse-7: A randomized, placebo-controlled, Phase 2a evaluating the impact of IL-7 immunotherapy on CD4 count, risks of severe haematological toxicity and tumor progression in metastatic breast cancer patients. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr CT333. doi:10.1158/1538-7445.AM2014-CT333 [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01368107&atom=%2Fcanres%2F74%2F19_Supplement%2FCT333.atom" @default.
• W2052612797 created "2016-06-24" @default.
• W2052612797 creator A5006675365 @default.
• W2052612797 creator A5008727148 @default.
• W2052612797 creator A5009371827 @default.
• W2052612797 creator A5016527565 @default.
• W2052612797 creator A5019588141 @default.
• W2052612797 creator A5020487290 @default.
• W2052612797 creator A5022767218 @default.
• W2052612797 creator A5022848420 @default.
• W2052612797 creator A5024404992 @default.
• W2052612797 creator A5025761056 @default.
• W2052612797 creator A5025970784 @default.
• W2052612797 creator A5026098825 @default.
• W2052612797 creator A5038384830 @default.
• W2052612797 creator A5041410352 @default.
• W2052612797 creator A5042202815 @default.
• W2052612797 creator A5048323312 @default.
• W2052612797 creator A5048784388 @default.
• W2052612797 creator A5057293211 @default.
• W2052612797 creator A5073434591 @default.
• W2052612797 creator A5075745866 @default.
• W2052612797 creator A5081734552 @default.
• W2052612797 creator A5081828105 @default.
• W2052612797 creator A5083175355 @default.
• W2052612797 date "2014-09-30" @default.
• W2052612797 modified "2023-10-18" @default.
• W2052612797 title "Abstract CT333: Elypse-7: A randomized, placebo-controlled, Phase 2a evaluating the impact of IL-7 immunotherapy on CD4 count, risks of severe haematological toxicity and tumor progression in metastatic breast cancer patients" @default.
• W2052612797 doi "https://doi.org/10.1158/1538-7445.am2014-ct333" @default.
• W2052612797 hasPublicationYear "2014" @default.
• W2052612797 type Work @default.
• W2052612797 sameAs 2052612797 @default.
• W2052612797 citedByCount "0" @default.
• W2052612797 crossrefType "proceedings-article" @default.
• W2052612797 hasAuthorship W2052612797A5006675365 @default.
• W2052612797 hasAuthorship W2052612797A5008727148 @default.
• W2052612797 hasAuthorship W2052612797A5009371827 @default.
• W2052612797 hasAuthorship W2052612797A5016527565 @default.
• W2052612797 hasAuthorship W2052612797A5019588141 @default.
• W2052612797 hasAuthorship W2052612797A5020487290 @default.
• W2052612797 hasAuthorship W2052612797A5022767218 @default.
• W2052612797 hasAuthorship W2052612797A5022848420 @default.
• W2052612797 hasAuthorship W2052612797A5024404992 @default.
• W2052612797 hasAuthorship W2052612797A5025761056 @default.
• W2052612797 hasAuthorship W2052612797A5025970784 @default.
• W2052612797 hasAuthorship W2052612797A5026098825 @default.
• W2052612797 hasAuthorship W2052612797A5038384830 @default.
• W2052612797 hasAuthorship W2052612797A5041410352 @default.
• W2052612797 hasAuthorship W2052612797A5042202815 @default.
• W2052612797 hasAuthorship W2052612797A5048323312 @default.
• W2052612797 hasAuthorship W2052612797A5048784388 @default.
• W2052612797 hasAuthorship W2052612797A5057293211 @default.
• W2052612797 hasAuthorship W2052612797A5073434591 @default.
• W2052612797 hasAuthorship W2052612797A5075745866 @default.
• W2052612797 hasAuthorship W2052612797A5081734552 @default.
• W2052612797 hasAuthorship W2052612797A5081828105 @default.
• W2052612797 hasAuthorship W2052612797A5083175355 @default.
• W2052612797 hasConcept C121608353 @default.
• W2052612797 hasConcept C126322002 @default.
• W2052612797 hasConcept C142724271 @default.
• W2052612797 hasConcept C143998085 @default.
• W2052612797 hasConcept C203092338 @default.
• W2052612797 hasConcept C204787440 @default.
• W2052612797 hasConcept C27081682 @default.
• W2052612797 hasConcept C2775930923 @default.
• W2052612797 hasConcept C2776694085 @default.
• W2052612797 hasConcept C2777063308 @default.
• W2052612797 hasConcept C2777701055 @default.
• W2052612797 hasConcept C2778248108 @default.
• W2052612797 hasConcept C2778850193 @default.
• W2052612797 hasConcept C31760486 @default.
• W2052612797 hasConcept C530470458 @default.
• W2052612797 hasConcept C535046627 @default.
• W2052612797 hasConcept C71924100 @default.
• W2052612797 hasConcept C90924648 @default.
• W2052612797 hasConceptScore W2052612797C121608353 @default.
• W2052612797 hasConceptScore W2052612797C126322002 @default.
• W2052612797 hasConceptScore W2052612797C142724271 @default.
• W2052612797 hasConceptScore W2052612797C143998085 @default.
• W2052612797 hasConceptScore W2052612797C203092338 @default.
• W2052612797 hasConceptScore W2052612797C204787440 @default.
• W2052612797 hasConceptScore W2052612797C27081682 @default.
• W2052612797 hasConceptScore W2052612797C2775930923 @default.
• W2052612797 hasConceptScore W2052612797C2776694085 @default.
• W2052612797 hasConceptScore W2052612797C2777063308 @default.
• W2052612797 hasConceptScore W2052612797C2777701055 @default.
• W2052612797 hasConceptScore W2052612797C2778248108 @default.
• W2052612797 hasConceptScore W2052612797C2778850193 @default.
• W2052612797 hasConceptScore W2052612797C31760486 @default.
• W2052612797 hasConceptScore W2052612797C530470458 @default.
• W2052612797 hasConceptScore W2052612797C535046627 @default.
• W2052612797 hasConceptScore W2052612797C71924100 @default.
• W2052612797 hasConceptScore W2052612797C90924648 @default.
• W2052612797 hasLocation W20526127971 @default.
• W2052612797 hasOpenAccess W2052612797 @default.
• W2052612797 hasPrimaryLocation W20526127971 @default.
• W2052612797 hasRelatedWork W1995109850 @default.
• W2052612797 hasRelatedWork W2315556735 @default.
• W2052612797 hasRelatedWork W2397636278 @default.
• W2052612797 hasRelatedWork W2402208612 @default.

• next